Izaguirre ÁR, Zaldívar AH

Idioma: Español
Referencias bibliográficas: 36
Paginas: 7-10
Archivo PDF: 56.10 Kb.

FRAGMENTO

El fibrinógeno (FG) es la proteína de la coagulación más abundante en la circulación. Es precursor de la fibrina, principal componente del trombo. La concentración plasmática de FG se incrementa durante la inflamación, por lo que es considerado uno de los indicadores del estado inflamatorio.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Green FR: Fibrinogen polymorphisms and atherothrombotic disease. Ann NY Acad Sci 2001; 936: 549-559.

2. Thomas AE, Green FR, Kelleher CH, Wilkesb HC, Brennan PJ, Meade TW, et al: Variation in the promoter region of the beta fibrinogen gene is associated with plasma fibrinogen levels in smokers and no-smokers. Thromb Haemost 1991; 65: 487-490.

3. Iacoviello L, Vischetti M, Zito F, Benedetta M: Genes encoding fibrinogen and cardiovascular risk. Hypertension 2001; 38: 1199-1203.

4. Humphries SE, Loung LA, Montgomery HE, Day I, Mohamed V, Yudkin J: Gene-environment interaction in the determinations of levels of plasma fibrinogen. Thromb Haemost 1999; 82: 818-825.

5. Basso F, Lowe GD, Rumley A, McMahon AD, Humphries SE: Interleukin-6-174G > C polymorphism and risk of coronary heart disease in West of Scotland coronary prevention study (WOSCOPS). Arterioscler Thromb Vasc Biol 2002; 22: 599-604.

6. Fenf D, Lindpaintner K, Larson MG, O’Donnell CJ, Lipinska I, Sutherland PA, et al: Platelet gycoprotein IIIa Pl(a) polymorphism, fibrinogen, and platelet aggregability: the Framingham Heart Stuply. Circulation 2001; 104: 140-144.

7. Izaguirre R, Ruiz de Chávez A, Villavicencio R, Gómez A, Mar R, Spíndola C, Casanova J: Variaciones en la hemostasia y fibrinólisis durante el tratamiento del infarto agudo del miocardio con activador tisular del plasminógeno. Arch Inst Cardiol Mex 1993; 63: 235-240.

8. Gold HK, Leinbach RC, Garabedian HD, Yasuda T, Johns JA, Grossbard EB, et al: Acute coronary reocclusion after thrombolysis with recombinant tissue-type plasminogen activator. Prevention by maintenance infusion. Circulation 1986; 73: 347-352.

9. Smith E, Keen GA, Grant A: Fate of fibrinogen in human arterial intima. Arteriosclerosis 1990; 10: 263-275.

10. Otto C, Richter WO, Schwandt P: Contribution of fibrinogen and lipoproteins to plasma viscosity in hypercholesterolemia and hypertriglyceridemia: evaluation by selective depletion of low-density lipoproteins or fibrinogen. Metabolism 2000; 49: 810-813.

11. Tataru MC, Schulte H, Von Eckardstein A, Heinrich J, Assmann G, Koehler E: Plasma fibrinogen in relation to the severity of arteriosclerosis in patients with stable angina pectoris after myocardial infarction. Coron Artery Dis 2001; 12: 157-165.

12. Lowe GD, Fowkes FG, Dawes J, Donnan PT, Lennie SE, Housley E: Blood viscosity, fibrinogen and activation of coagulation and leukocytes in peripheal arterial disease and the normal population in the Edinburgh Artery Study. Circulation 1993; 87: 1915-1920.

13. Montalescot G, Collet JP, Choussat R, Thomas D: Fibrinogen as a risk factor for coronary heart disease. Eur Heart J 1998; 19: H11-H17.

14. Wilhemsen L, Svardsudd K, Korsan K, Larsson B, Welin L, Tibblin G: Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-505.

15. Qizilbash N, Jones L, Warlow C, Mann J: Fibrinogen and lipid concentrations as risk factors for transient ischaemic attacks and minor ischaemic strokes. Br J Med L 1991; 303: 605-609.

16. Bainton D, Sweetnam P, Baker I, Elwood P: Peripheal vascular disease. Consequence for survival and association with risk factors in the Speedwell Prospective Heart Disease Study. Br Heart J 1994; 72: 128-132.

17. Colas JL, Montalescot G, Tribouilloy C: Fibrinogen: a cardiovascular risk factor. Presse Med 2000; 29: 1862-1866.

18. Meade TW, North WR, Chakrabarti R, Stirling Y, Haines AP, Thompson SG, et al: Haemostatic function and cardiovascular death: Early results of a Prospective study. Lancet 1980; 1: 1050-1054.

19. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, et al: Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-537.

20. Ernst E, Resch K: Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature. Ann Intern Med 1993; 118: 956-963.

21. Danesh J, Collins R, Appleby P, Peto R: Fibrinogen, C-reactive protein, albumin or white cell count: meta-analyses of prospective sudies of coronary heart disease. JAMA 1998; 279: 1477-1482.

22. Maresca G, Di Blasio A, Marchili R, Di Minno G: Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. Arterioscler Thromb Vasc Biol 1999; 19: 1368-1377.

23. Acevedo M, Foody JM, Pearce GL, Sprecher DL: Fibrinogen: associations with cardiovascular events in an outpatient clinic. Am Heart J 2002; 143: 277-282.

24. Izaguirre R, De la Peña A, Barinagarrementería F, González H, Ramírez AE, Ruiz JL, et al: Effect of clopidogrel on platelet aggregation and plasma concentration of fibrinogen in subjects with cerebral or coronary atherosclerotic disease. Clin Appl Thromb Hemost 2002; 8: 1169-177.

25. Ma J, Hennekens C, Ridker P, Stumpfer M. A Prospective study of fibrinogen and risk of myocardial infarction in the Physicians’ Health Study. J Am Coll Cardiol 1999; 33: 1347-1352.

26. Roeters JE, Westerveld HT, Erkelens DW, Van Der Wall E: Risk factors for coronary heart disease: implications of gender. Cardiovascular Res 2002; 53: 538-549.

27. Wannamethee SG, Lowe GD, Whincup PH, Rumley A, Walker M, Lennon L. Physical activity and hemostatic and inflammatory variables in elderly men. Circulation 2002; 105: 1785-1790.

28. Kannel WB, Dágostino RB, Belanger AJ: Fibrinogen, cigarrete smoking and risk of cardiovascular disease: insights from the Framingham Study. Am Heart J 1987; 113: 1006-1010.

29. Cantin B, Despres JP, Lamarche B, Moorjani S, Lupien PJ, Bogaty P, et al: Association of fibrinogen and lipoprotein(a) as a coronary heart disease risk factor in men (The Quebec Cardiovascular Study). Am J Cardiol 2002; 89: 662-666.

30. Stout RW, Crawford V: Seasonal variations in fibrinogen concentrations among elderly people. Lancet 1991; 339: 9-13.

31. Woodhouse PR, Khaw KT, Plummer M, Foley A, Meade TW: Seasonal variations of plasma fibrinogen and factor VII activity in the elderly: winter infections and death from cardiovascular disease. Lancet 1994; 343: 345-349.

32. Van del Bom J, De Maat M, Bots M, Hofman A, Kluyft C, Grobee D: Seasonal variation in fibrinogen in the Rotterdam study. Throm Haemost 1997; 78: 1059-1062.

33. Rosenson RS, Mosca L, Staffileno BA, Tangney CC: Variability in fibrinogen measurements: an obstacle to cardiovascular risk stratification. Atherosclerosis 2001; 159: 225-230.

34. Folsom A, Wu K, Rosamond W, Sharret A, Chambless L: Prospective study of hemostatic factors and incidence of coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997; 96: 1102-1108.

35. Chandler W, Rodgers GM, Sprouse JT, Thompson AR: Elevated hemostatic factor levels as potential risk factors for thrombosis. Arch Pathol Lab Med 2002; 126: 1405-1414.

36. Stec J, Silbershatz H, Tofler G, Matheney T, Sutherland P, Pipinska I, et al: Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham offspring population. Circulation 2000; 102: 1634-1638.